202 related articles for article (PubMed ID: 29540104)
1. Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastomeric pump supporting transition of the EPOCH regimen to outpatient care.
Svirskis D; Behera S; Naidoo N; Beachman J; Raina T; Zhou Y; Berkahn L; Costello I; Gu Y
J Oncol Pharm Pract; 2019 Jun; 25(4):831-840. PubMed ID: 29540104
[TBL] [Abstract][Full Text] [Related]
2. In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag.
Li J; Yao C; Xu Y; Ping P; Yin H; Sun Y
J Clin Pharm Ther; 2019 Dec; 44(6):875-882. PubMed ID: 31529525
[TBL] [Abstract][Full Text] [Related]
3. Making moves: Transitioning R-EPOCH to the ambulatory setting.
Martin AL; Frank JP; Waggoner ML
J Oncol Pharm Pract; 2018 Dec; 24(8):617-622. PubMed ID: 28782408
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin Lymphoma.
Evans SS; Gandhi AS; Clemmons AB; DeRemer DL
J Pharm Pract; 2017 Aug; 30(4):400-405. PubMed ID: 27432462
[TBL] [Abstract][Full Text] [Related]
5. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
Stewart JT; Warren FW; King DT; Venkateshwaran TG; Ponder GW; Fox JL
Am J Health Syst Pharm; 1997 Apr; 54(8):915-20. PubMed ID: 9114924
[No Abstract] [Full Text] [Related]
6. Impact of transitioning inpatient chemotherapy regimens to the outpatient setting.
Corsi MP; Shea K; W Knoebel R
J Oncol Pharm Pract; 2020 Sep; 26(6):1324-1330. PubMed ID: 31822200
[TBL] [Abstract][Full Text] [Related]
7. Stability of intravenous admixtures of doxorubicin and vincristine.
Beijnen JH; Neef C; Meuwissen OJ; Rutten JJ; Rosing H; Underberg WJ
Am J Hosp Pharm; 1986 Dec; 43(12):3022-7. PubMed ID: 3812509
[TBL] [Abstract][Full Text] [Related]
8. Stability of Cefazolin in Polyisoprene Elastomeric Infusion Devices.
Patel RP; Jacob J; Sedeeq M; Ming LC; Wanandy T; Zaidi STR; Peterson GM
Clin Ther; 2018 Apr; 40(4):664-667. PubMed ID: 29496321
[TBL] [Abstract][Full Text] [Related]
9. Physical and chemical stability of etoposide phosphate solutions.
Zhang Y; Trissel LA
J Am Pharm Assoc (Wash); 1999; 39(2):146-50. PubMed ID: 10079650
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices.
Chen IH; Martin EK; Nicolau DP; Kuti JL
Clin Ther; 2020 Apr; 42(4):606-613. PubMed ID: 32139176
[TBL] [Abstract][Full Text] [Related]
11. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.
Wilson WH; Bryant G; Bates S; Fojo A; Wittes RE; Steinberg SM; Kohler DR; Jaffe ES; Herdt J; Cheson BD
J Clin Oncol; 1993 Aug; 11(8):1573-82. PubMed ID: 7687667
[TBL] [Abstract][Full Text] [Related]
12. Reducing Hospitalizations: Institution of Outpatient Infusional EPOCH-Based Chemotherapy at a Safety Net Hospital.
Keshvani N; Hon M; Gupta A; Brown TJ; Roy L; Marley E; Lindsey S; Johnson DH; Sadeghi N; Li HC
J Oncol Pract; 2019 Aug; 15(8):e644-e651. PubMed ID: 31206340
[TBL] [Abstract][Full Text] [Related]
13. Ceftolozane-tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study.
Raby E; Naicker S; Sime FB; Manning L; Wallis SC; Pandey S; Roberts JA
Eur J Hosp Pharm; 2020 Mar; 27(e1):e84-e86. PubMed ID: 32296512
[TBL] [Abstract][Full Text] [Related]
14. Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs.
Rochard EB; Barthès DM; Courtois PY
Am J Hosp Pharm; 1992 Mar; 49(3):619-23. PubMed ID: 1598939
[TBL] [Abstract][Full Text] [Related]
15. Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center.
Li W; Richter KA; Tobon KA; McCarthy KT; Kubal TE
J Oncol Pharm Pract; 2021 Oct; 27(7):1684-1690. PubMed ID: 33092499
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy.
Wilson WH; Jamis-Dow C; Bryant G; Balis FM; Klecker RW; Bates SE; Chabner BA; Steinberg SM; Kohler DR; Wittes RE
J Clin Oncol; 1995 Aug; 13(8):1985-94. PubMed ID: 7636539
[TBL] [Abstract][Full Text] [Related]
17. Stability of meropenem in portable elastomeric infusion devices: which protocol should be implemented in clinical practice?
Esteban-Cartelle B; Serrano DR; Pérez Menéndez-Conde C; Vicente-Oliveros N; Álvarez-Díaz A; Abete JF; Martín-Dávila P
Microbiol Spectr; 2024 Feb; 12(2):e0206323. PubMed ID: 38230930
[TBL] [Abstract][Full Text] [Related]
18. Compatibility and stability of vincristine sulfate, doxorubicin hydrochloride, and etoposide in 0.9% sodium chloride injection.
Wolfe JL; Thoma LA; Du C; Goldspiel BR; Gallelli JF; Grimes GJ; Potti GK
Am J Health Syst Pharm; 1999 May; 56(10):985-9. PubMed ID: 10365723
[No Abstract] [Full Text] [Related]
19. Stability of doxorubicin hydrochloride and vincristine sulfate in two portable infusion-pump reservoirs.
Nyhammar EK; Johansson SG; Seiving BE
Am J Health Syst Pharm; 1996 May; 53(10):1171-3. PubMed ID: 8734681
[No Abstract] [Full Text] [Related]
20. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
Huang HQ; Jiang WQ; Wang W; Zhou ZM; Xia ZJ; Lin XB; Li YH; Xu RH; Zhang L; Xu GC; Sun XF; Liu DG; He YJ; Guan ZZ
Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
